Kala Pharmaceuticals Inc (KALA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8086
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company that offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, meibomian gland disease, ocular inflammation, and dry eye disease. It also develops a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). Kala Pharmaceuticals is funded by life science investors such as Lux Capital Management, Cam Capital, Longitude Capital Management, RA Capital Management, Third Rock Ventures and others. The company offers its products across the US. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc (KALA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kala Pharma Raises USD68 Million in Series C Financing Round 11
Kala Pharma Raises USD7 Million in Venture Financing 13
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 14
Kala Pharma Raises US$11.5 Million In Series A Financing 16
Kala Pharma Raises US$6.2 Million In Seed Financing 18
Equity Offering 19
Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19
Kala Pharma Raises USD103.5 Million in IPO 21
Kala Pharmaceuticals Inc – Key Competitors 23
Kala Pharmaceuticals Inc – Key Employees 24
Kala Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Kala Pharmaceuticals reports second quarter 2018 financial results 26
Mar 26, 2018: Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 28
Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 30
Corporate Communications 32
Mar 05, 2018: Kala Pharmaceuticals Names Gregory Perry As Board Director and as Audit Committee Chair 32
Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 33
Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 34
Product News 35
08/23/2018: Kala Pharmaceuticals announces FDA approval of INVELTYS for the treatment of post-operative inflammation and pain following ocular surgery 35
05/09/2018: Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch 37
01/05/2018: Kala Pharmaceuticals Announces New Drug Application For Inveltys (KPI-121 1%) Has Been Accepted For Review By The U.S. Food And Drug Administration 38
Product Approvals 39
Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 39
Clinical Trials 40
Jul 31, 2018: Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease 40
Jun 19, 2018: Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan 41
Apr 09, 2018: Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS 43
Jan 05, 2018: Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease 44
May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 46
Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kala Pharma Raises USD68 Million in Series C Financing Round 11
Kala Pharma Raises USD7 Million in Venture Financing 13
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 14
Kala Pharma Raises US$11.5 Million In Series A Financing 16
Kala Pharma Raises US$6.2 Million In Seed Financing 18
Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19
Kala Pharma Raises USD103.5 Million in IPO 21
Kala Pharmaceuticals Inc, Key Competitors 23
Kala Pharmaceuticals Inc, Key Employees 24
Kala Pharmaceuticals Inc, Other Locations 25

List of Figures
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Kala Pharmaceuticals Inc (KALA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ingersoll-Rand plc:企業の戦略・SWOT・財務情報
    Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report Summary Ingersoll-Rand plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Novolex Holdings, Inc.:企業の戦略的SWOT分析
    Novolex Holdings, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • 1-800-FLOWERS.COM, Inc.:企業の戦略・SWOT・財務分析
    1-800-FLOWERS.COM, Inc. - Strategy, SWOT and Corporate Finance Report Summary 1-800-FLOWERS.COM, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Manchester United Plc:企業の戦略・SWOT・財務情報
    Manchester United Plc - Strategy, SWOT and Corporate Finance Report Summary Manchester United Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bourbon SA (GBB):企業の戦略的SWOT分析
    Bourbon SA (GBB) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Emera Inc (EMA):企業の財務・戦略的SWOT分析
    Emera Inc (EMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Merck KGaA (MRK)-医療機器分野:企業M&A・提携分析
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • Genomind Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genomind Inc (Genomind) is a personalized medicine company that provides genetic testing services. The company offers Genecept Assay, a pharmacogenetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. Its test is used to guide treatment fo …
  • TriMas Corporation:企業のM&A・事業提携・投資動向
    TriMas Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TriMas Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • AEON Credit Service (Asia) Co., Ltd.:企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Illumina Inc (ILMN):企業の財務・戦略的SWOT分析
    Illumina Inc (ILMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Cancer Genetics Inc (CGIX)-医療機器分野:企業M&A・提携分析
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic inform …
  • InvitroCue Ltd (IVQ):企業の財務・戦略的SWOT分析
    Summary InvitroCue Ltd (InvitroCue), formerly Bunuru Corporation Ltd, is a provider of bio-analytic solutions. The company provides digital pathology services such as digitization, sample preparation, staining, computer aided diagnosis and consultation, telepathology, automated reporting and image a …
  • SciBase AB (SCIB):企業の財務・戦略的SWOT分析
    Summary SciBase AB (SciBase) is a medical technology company that offers non-invasive detection and monitoring of skin tissue alterations. The company develops point of care device for the accurate detection of malignant melanoma. It offers electrical impedance spectroscopy which uses the varying el …
  • FleetPride, Inc.:企業のM&A・事業提携・投資動向
    FleetPride, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's FleetPride, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • LA DORIA S.p.A.:企業の戦略・SWOT・財務情報
    LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report Summary LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Lear Corp (LEA):企業の財務・戦略的SWOT分析
    Lear Corp (LEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. ValiRx uses GeneICE technology, which enables silen …
  • PCI Pharma Services:製薬・医療:M&Aディール及び事業提携情報
    Summary PCI Pharma Services (PCI) is a pharmaceutical service provider that offers clinical, manufacturing and packaging solutions. The company offers clinical services such as clinical supplies management, clinical planning and support, project management, IVRS-IWRS, support services and data acces …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆